SCHEMBL19503849

SCHEMBL19503849

CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCN(C(=O)CN=[N+]=[N-])CC5)CSc5ccccc5)c([S+]([O-])C(F)(F)F)c4)cc3)CC2)C1

nearest known ligand 0.70

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ BCL2L1 Q07817 18/20 0.70
▸ BCL2 P10415 14/20 0.70
▸ BAD Q92934 4/20 0.70
▸ BCL2L2 Q92843 2/20 0.70
▸ BCL2L11 O43521 1/20 0.70
▸ CYP2C9 P11712 1/20 0.70
▸ MCL1 Q07820 1/20 0.70
▸ ASPH Q12797 1/20 0.70
▸ VHL P40337 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21896505 0.95 BCL2L1 (0.69) BCL2L1BCL2BADBCL2L2BCL2L11
SCHEMBL19475758 0.92 BCL2L1 (0.83) BCL2L1BCL2BADBCL2L2BCL2L11
SCHEMBL19475755 0.92 BCL2L1 (0.83) BCL2L1BCL2BADBCL2L2BCL2L11
SCHEMBL19503614 0.87 BCL2L1 (0.81) BCL2L1BCL2BADBCL2L2BCL2L11
SCHEMBL20956661 0.87 BCL2L1 (0.81) BCL2L1BCL2BADBCL2L2BCL2L11
SCHEMBL19475889 0.84 BCL2L1 (0.91) BCL2L1BCL2BADBCL2L2BCL2L11
SCHEMBL19475888 0.84 BCL2L1 (0.91) BCL2L1BCL2BADBCL2L2BCL2L11
SCHEMBL21896504 0.84 BCL2L1 (0.75) BCL2L1BCL2BADBCL2L2BCL2L11
SCHEMBL5522380 0.83 BCL2L1 (0.87) BCL2L1BCL2BADBCL2L2BCL2L11
SCHEMBL19145093 0.83 BCL2L1 (0.93) BCL2L1BCL2BADBCL2L2BCL2L11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017184995-A1 COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF BIOVENTURES, LLC (US) 2017-10-26 — — WO disclosed
Send feedback